Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Long-Term Deferred Tax (2016)

Apyx Medical filings provide 7 years of Long-Term Deferred Tax readings, the most recent being $21000.0 for Q2 2016.

  • On a quarterly basis, Long-Term Deferred Tax changed N/A to $21000.0 in Q2 2016 year-over-year; TTM through Jun 2016 was $21000.0, a N/A change, with the full-year FY2015 number at $25000.0, down 99.54% from a year prior.
  • Long-Term Deferred Tax hit $21000.0 in Q2 2016 for Apyx Medical, down from $39000.0 in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $5.4 million in Q4 2014 to a low of $21000.0 in Q2 2016.
  • Median Long-Term Deferred Tax over the past 5 years was $1.4 million (2012), compared with a mean of $2.1 million.
  • Biggest five-year swings in Long-Term Deferred Tax: skyrocketed 66.87% in 2012 and later plummeted 99.54% in 2015.
  • Apyx Medical's Long-Term Deferred Tax stood at $2.5 million in 2012, then skyrocketed by 35.5% to $3.4 million in 2013, then surged by 58.44% to $5.4 million in 2014, then plummeted by 99.54% to $25000.0 in 2015, then decreased by 16.0% to $21000.0 in 2016.
  • The last three reported values for Long-Term Deferred Tax were $21000.0 (Q2 2016), $39000.0 (Q1 2016), and $25000.0 (Q4 2015) per Business Quant data.